Evaluation of rs781673405, rs1244378045, rs767450259, rs750556128, rs369143448, rs143353036, and rs759369504 mutations in terms of polymorphism in diabetic obese and non-diabetic obese individuals.
{"title":"Evaluation of rs781673405, rs1244378045, rs767450259, rs750556128, rs369143448, rs143353036, and rs759369504 mutations in terms of polymorphism in diabetic obese and non-diabetic obese individuals.","authors":"Saadet Busra Aksoyer Sezgin, Sermin Durak, Faruk Celik, Varol Guler, Aysegul Sarikaya, Umit Zeybek","doi":"10.1007/s12020-025-04184-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Obesity is among the important healthcare issues in which there is an abnormal increase in body fat because energy intake is higher than energy expenditure. The Tumor Necrosis Factor (TNF)-alpha overexpression in adipose tissue plays important roles in mediating obesity and insulin resistance. \"TNF-related apoptosis-inducing Ligand (TRAIL(TNSF10))\", which is a member of the TNF family, is expressed as a Type-II Transmembrane Protein with an effect on the development of obesity and diabetes.</p><p><strong>Methods: </strong>The rs781673405, rs1244378045, rs767450259, rs750556128, rs369143448, rs143353036, and rs759369504 polymorphisms of TRAIL, which were determined to play protective roles against diabetes, were evaluated with the RT-qPZR Method in the present study.</p><p><strong>Results: </strong>It was found that the genotype distribution of TRAIL rs767450259 Polymorphism was significant and the T-Allele had protective effects against diabetic obesity. It was also found that the G-Allele of the rs369143448 Polymorphism had protective roles against diabetic obesity. It was shown that carrying the A-Allele in the rs750556128 Polymorphism might increase the risk of obesity in diabetic patients by 1.3-fold.</p><p><strong>Conclusions: </strong>The present study makes a significant contribution to the literature data because it is the first to investigate these polymorphisms.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04184-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Obesity is among the important healthcare issues in which there is an abnormal increase in body fat because energy intake is higher than energy expenditure. The Tumor Necrosis Factor (TNF)-alpha overexpression in adipose tissue plays important roles in mediating obesity and insulin resistance. "TNF-related apoptosis-inducing Ligand (TRAIL(TNSF10))", which is a member of the TNF family, is expressed as a Type-II Transmembrane Protein with an effect on the development of obesity and diabetes.
Methods: The rs781673405, rs1244378045, rs767450259, rs750556128, rs369143448, rs143353036, and rs759369504 polymorphisms of TRAIL, which were determined to play protective roles against diabetes, were evaluated with the RT-qPZR Method in the present study.
Results: It was found that the genotype distribution of TRAIL rs767450259 Polymorphism was significant and the T-Allele had protective effects against diabetic obesity. It was also found that the G-Allele of the rs369143448 Polymorphism had protective roles against diabetic obesity. It was shown that carrying the A-Allele in the rs750556128 Polymorphism might increase the risk of obesity in diabetic patients by 1.3-fold.
Conclusions: The present study makes a significant contribution to the literature data because it is the first to investigate these polymorphisms.
期刊介绍：
Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology.
Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted.
Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
